Remdesivir, sold under the brand name Veklury, was conditionally approved in Europe in July for treating COVID-19 in adults and adolescents with pneumonia requiring oxygen support. The European Medicines Agency (EMA) said to arrive at the conclusion the panel (PRAC) had assessed data provided by the U.S.-based drugmaker, analyses of reported adverse reactions, data from trials and published work on COVID-19 patients with acute kidney injury.